Could Argenx SE – American Depositary Shares (NASDAQ:ARGX) Go Down After Its Newest Short Interest Report?

April 18, 2018 - By Clifton Ray

The stock of Argenx SE – American Depositary Shares (NASDAQ:ARGX) registered a decrease of 13.81% in short interest. ARGX’s total short interest was 128,600 shares in April as published by FINRA. Its down 13.81% from 149,200 shares, reported previously. With 114,400 shares average volume, it will take short sellers 1 days to cover their ARGX’s short positions. The short interest to Argenx SE – American Depositary Shares’s float is 0.58%.

The stock increased 0.63% or $0.54 during the last trading session, reaching $85.93. About 5,921 shares traded. argenx SE (NASDAQ:ARGX) has 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.72 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: